South Korea Biopharmaceutical Contract Manufacturing Market Size, Share, By Source (Non-mammalian, Mammalian), By Service (Packaging & Labelling, Process Development, Downstream, Upstream, Fill & Finish Operations, Analytical & QC Studies, Others), By Drug Type (Biosimilar, Biologics, Monoclonal Antibodies (mob’s), Recombinant Proteins, Vaccines, Antisense, RNAi, & Molecular Therapy, Others), By Type (Drug Substance, Finished Drug Product), By Scale of Operation (Clinical, Commercial), By Therapeutic Area (Oncology, Infectious Diseases, Cardiovascular Diseases, Metabolic Diseases, Neurology, Autoimmune Diseases, Others), South Korea Biopharmaceutical Contract Manufacturing Market Insights, Industry Trend, Forecasts to 2035.

South Korea Biopharmaceutical Contract Manufacturing Market Insights Forecasts to 2035

• South Korea Biopharmaceutical Contract Manufacturing Market Size 2024: USD 1098.6 Mn
• South Korea Biopharmaceutical Contract Manufacturing Market Size 2035:  USD 3987.5 Mn
• South Korea Biopharmaceutical Contract Manufacturing Market CAGR 2024: 12.43%
• South Korea Biopharmaceutical Contract Manufacturing Market Segments: Source, Service, Drug Type, Type, Scale of Operation, and Therapeutic Area

The South Korea Biopharmaceutical Contract Manufacturing Market Size is a service where the production of biologics is carried out by third parties. These include monoclonal antibodies, vaccines, recombinant proteins, cell and gene therapies, as well as other complex therapeutic products. Such services are thus the requirements of biopharma companies that lead to the provision of specialized facilities, regulatory compliance, scalable manufacturing, and quality assurance for clinical and commercial production. The contract manufacturing providers manage upstream and downstream processes, formulation, fill finish, and packaging in order to serve both domestic and global clients that are developing innovative biologic therapies.

Biopharmaceuticals Contract Manufacturing is used in the production, supply, and development of clinical trial materials, commercial biologic drugs, process scale, up, and technology transfer projects. South Korea exports biologics and contract manufacturing services to the global market and at the same time, imports advanced raw materials and end products, Therefore, import and export activities play a role in the country. Innovations in technology such as single, use bioreactors, continuous processing, modular facilities, advanced analytics, and automation lead to better production efficiency, minimization of contamination risk, and faster time, to, market. Government initiatives to boost bio industrial growth, regulatory harmonization, and investment in bio manufacturing infrastructure promote the expansion of the sector. The sources of new avenues that are expected to unfold depend on the growing global demand for biologics, the increasing outsourcing of R&D, the development of biosimilar, as well as the capacity expansion for high, complexity therapies in South Korea.

Market Dynamics of the South Korea Biopharmaceutical Contract Manufacturing Market:

The market is propelled by the growing research & development activities in the area of biologics, increased demand for monoclonal antibodies, vaccines, cell & gene therapies, and the need for specialty manufacturing units designed for strict quality & regulatory requirements. The outsourcing trend provides biopharmaceutical companies with ways to decrease capex, accelerate time-to-market, and gain access to new & modern sophisticated manufacturing capabilities.

High costs of biopharmaceutical contract manufacturing, regulatory approval, shortage of qualified personnel, and scaling and quality standards limit the growth of the industry. Relying on imported raw materials and technology and high expertise levels add to the difficulties of doing business within the industry.

Areas of opportunity lie in the growing demand for capacity for high complexity therapies, incorporating single-use and modular bio manufacturing platforms, engaging with the development of biosimilar and cell and gene therapy, and advancing through the application of automation and analytics solutions for greater efficiency. Biopharma partnerships between local and foreign companies, government-driven bio manufacturing initiatives, and the outsourcing of clinical trials also serve to propel the market forward.

Market Segmentation

The South Korea biopharmaceutical contract manufacturing market share is classified into source, service, drug type, type, scale of operation, and therapeutic area.

By Source:

The South Korea Biopharmaceutical Contract Manufacturing Market Size is divided by source into non-mammalian and mammalian. Among these, the mammalian segment dominated the share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. Mammalian systems lead the pack as they can produce complex biologics, monoclonal antibodies, and vaccines through proper protein folding and post, translational modifications, resulting in higher therapeutic efficacy and meeting global regulatory standards, thus they are essential for both clinical and commercial scale production.

By Service:

The South Korea Biopharmaceutical Contract Manufacturing Market Size is divided by service into packaging & labelling, process development, downstream, upstream, fill & finish operations, analytical & QC studies, and others. Among these, the upstream segment dominated the share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. Upstream processes contribute majority of the value as biologics become more complex, cell culture systems capable of high yields are needed, regulatory standards become more stringent, and advanced bioreactors and single, use technologies for biologics production at large scale are increasingly adopted.

By Drug Type:

The South Korea Biopharmaceutical Contract Manufacturing Market Size is divided by drug type into biosimilar, biologics, monoclonal antibodies (mAbs), recombinant proteins, vaccines, antisense, RNAi & molecular therapy, and others. Among these, the monoclonal antibodies (mAbs) segment dominated the share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. mAbs are leading the market because the global demand for oncology, autoimmune and infectious disease therapies is very high, the production requires complex processes, the cost of such treatments is high, and the manufacturing outsourcing trend to specialized CDMOs is increasing.

By Type:

The South Korea Biopharmaceutical Contract Manufacturing Market Size is divided by type into drug substance and finished drug product. Among these, the drug substance segment dominated the share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. Drug substance production mainly contributes to the total, firstly, it is crucial in determining the quality of the product and its compliance with GMP standards. Besides that, the production process requires high, level technical expertise and consumes a lot of resources for both upstream and downstream bioprocessing.

By Scale of Operation:

The South Korea Biopharmaceutical Contract Manufacturing Market Size is divided by scale of operation into clinical and commercial. Among these, the commercial segment dominated the share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. Commercial operations contribute the most as the world's demand for biologics keeps increasing, production volumes must be very large, there is the growth of biosimilar, and biopharma companies, both domestic and foreign, are strategically outsourcing to CDMOs that are cost, efficient and technologically advanced.

By Therapeutic Area:

The South Korea Biopharmaceutical Contract Manufacturing Market Size is divided by therapeutic area into oncology, infectious diseases, cardiovascular diseases, metabolic diseases, neurology, autoimmune diseases, and others. Among these, the oncology segment dominated the share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. Oncology is the leading disease area because of the upsurge in the number of cancer cases, the significant amount of money spent on R&D for targeted therapies, biologic treatments that are high in value, and an increasing trend of outsourcing monoclonal antibodies and immunotherapies manufacturing to contract manufacturing specialists.

Competitive Analysis:

The report offers the appropriate analysis of the key organisations/companies involved within the South Korea Biopharmaceutical Contract Manufacturing Market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market. 

Top Key Companies in South Korea Biopharmaceutical Contract Manufacturing Market:

• Samsung Biologics
• SK Bioscience Co., Ltd.
• Celltrion, Inc.
• GC Pharma (Green Cross Corporation)
• LG Chem Life Sciences (Contract Manufacturing Division)
• Hanmi Pharmaceutical Co., Ltd. (Contract Manufacturing Services)
• Dongkoo Bio & Pharma Co., Ltd.
• Daewoong Pharmaceutical Co., Ltd. (CMO/Contract Services)
• Pharmicell Co., Ltd.
• Genexine, Inc.
• Kolon Life Science, Inc.
• Hyundai Bioland Co., Ltd.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the Japan, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the South Korea biopharmaceutical contract manufacturing market based on the below-mentioned segments:

South Korea Biopharmaceutical Contract Manufacturing Market, By Source

• Non-mammalian
• Mammalian

South Korea Biopharmaceutical Contract Manufacturing Market, By Service

• Packaging & Labelling
• Process Development
• Downstream
• Upstream
• Fill & Finish Operations
• Analytical & QC Studies
• Others

South Korea Biopharmaceutical Contract Manufacturing Market, By Drug Type

• Biosimilar
• Biologics
• Monoclonal Antibodies (mAbs)
• Recombinant Proteins
• Vaccines
• Antisense, RNAi, & Molecular Therapy
• Others

South Korea Biopharmaceutical Contract Manufacturing Market, By Type

• Drug Substance
• Finished Drug Product

South Korea Biopharmaceutical Contract Manufacturing Market, By Scale of Operation

• Clinical
• Commercial

South Korea Biopharmaceutical Contract Manufacturing Market, By Therapeutic Area

• Oncology
• Infectious Diseases
• Cardiovascular Diseases
• Metabolic Diseases
• Neurology
• Autoimmune Diseases
• Others